$OGEN
ORAGENICS INC

2018 Q2 Form 10-Q Financial Statement

#000119312518164075 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.010M $800.0K $870.0K
YoY Change 27.85% -8.05% -12.51%
% of Gross Profit
Research & Development $1.272M $1.326M $1.122M
YoY Change 110.03% 18.15% -8.36%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $20.00K
YoY Change -100.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $2.284M $2.122M $1.988M
YoY Change 63.49% 6.74% -4.19%
Operating Profit -$2.284M -$2.122M -$1.988M
YoY Change 63.49% 6.74% -4.19%
Interest Expense $664.00 $837.00 $801.00
YoY Change -98.85% 4.49% 3.89%
% of Operating Profit
Other Income/Expense, Net $2.260K $2.307K $5.081K
YoY Change -98.71% -54.6% 685.32%
Pretax Income -$2.281M -$2.119M -$1.983M
YoY Change 86.84% 6.9% -4.41%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.281M -$2.119M -$1.983M
YoY Change 86.86% 6.89% -3.89%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$378.1K -$424.8K -$402.4K
COMMON SHARES
Basic Shares Outstanding 6.087M shares 4.928M shares 49.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.940M $4.760M $2.180M
YoY Change 88.52% 118.35% -35.31%
Cash & Equivalents $3.941M $4.758M $2.175M
Short-Term Investments
Other Short-Term Assets $1.260M $720.0K $110.0K
YoY Change -48.36% 554.55% -42.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.198M $5.480M $2.281M
YoY Change 14.85% 140.22% -40.51%
LONG-TERM ASSETS
Property, Plant & Equipment $10.64K $13.95K $69.43K
YoY Change -79.44% -79.91% -43.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.64K $13.95K $69.43K
YoY Change -79.44% -79.91% -43.26%
TOTAL ASSETS
Total Short-Term Assets $5.198M $5.480M $2.281M
Total Long-Term Assets $10.64K $13.95K $69.43K
Total Assets $5.209M $5.494M $2.351M
YoY Change 13.79% 133.72% -40.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.540M $1.110M $1.100M
YoY Change 45.28% 0.91% 11.11%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $20.00K $70.00K $60.00K
YoY Change 0.0% 16.67% -25.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.558M $1.179M $1.165M
YoY Change 43.8% 1.19% 7.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.558M $1.179M $1.165M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.560M $1.180M $1.170M
YoY Change -61.69% 0.85% 8.33%
SHAREHOLDERS EQUITY
Retained Earnings -$105.9M -$103.6M -$96.65M
YoY Change 8.16% 7.17% 7.73%
Common Stock $6.103K $5.187K $97.84M
YoY Change -99.99% -99.99% 5.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.651M $4.315M $1.186M
YoY Change
Total Liabilities & Shareholders Equity $5.209M $5.494M $2.351M
YoY Change 13.79% 133.72% -40.59%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.281M -$2.119M -$1.983M
YoY Change 86.86% 6.89% -3.89%
Depreciation, Depletion And Amortization $0.00 $10.00K $20.00K
YoY Change -100.0% -50.0% 0.0%
Cash From Operating Activities -$2.280M -$1.367M -$1.900M
YoY Change 28.81% -28.09% 17.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.460M -41.63K -4.951K
YoY Change -12.57% 740.84% -85.42%
NET CHANGE
Cash From Operating Activities -2.280M -1.367M -1.900M
Cash From Investing Activities
Cash From Financing Activities 1.460M -41.63K -4.951K
Net Change In Cash -820.0K -1.408M -1.905M
YoY Change 720.0% -26.09% 15.22%
FREE CASH FLOW
Cash From Operating Activities -$2.280M -$1.367M -$1.900M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
120000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6086635 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2175172
CY2018Q1 us-gaap Assets Current
AssetsCurrent
5480490
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101788731
CY2018Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1111441
CY2018Q1 us-gaap Assets
Assets
5494440
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4757863
CY2018Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4507863
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5186635 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2177425 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5186635 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
5187
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5494440
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1179204
CY2018Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
6100182
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
722627
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13950
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103578864
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
4315236
CY2018Q1 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
67763
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4080618
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17559 shares
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7193172
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101402570
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
818044
CY2017Q4 us-gaap Assets
Assets
7214831
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6166143
CY2017Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
5916143
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4928335 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2177425 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4928335 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4928
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7214831
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
898522
CY2017Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
6309608
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1027029
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21659
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101400797
CY2017 ogen Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
2177425 shares
CY2017 ogen Class Of Warrant Expired
ClassOfWarrantExpired
17559 shares
CY2017 ogen Class Of Warrant Exercised
ClassOfWarrantExercised
0 shares
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1905446
CY2017Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1200
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18035
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
-121
CY2017Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
160
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
865195
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
6316309
CY2017Q4 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
80478
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 ogen Stock Holders Equity Reverse Stock Split Conversion Ratio
StockHoldersEquityReverseStockSplitConversionRatio
0.10 pure
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4928335 shares
CY2017Q2 ogen Number Of Accredited Investors
NumberOfAccreditedInvestors
3 Investor
CY2018Q1 ogen Fractional Shares From Reverse Stock Split Share
FractionalSharesFromReverseStockSplitShare
0 shares
CY2018Q1 ogen Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2018-01-19
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1982575
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-121
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.40
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-174616
CY2017Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1982575
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-66764
CY2017Q1 us-gaap Interest Expense
InterestExpense
801
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1935
CY2017Q1 us-gaap Interest Paid
InterestPaid
801
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4951
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1987656
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1900495
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1982696
CY2017Q1 us-gaap Notes Assumed1
NotesAssumed1
31985
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1987656
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5081
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5147
CY2017Q1 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-35514
CY2017Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
53516
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1122461
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
172018
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
118502
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4919979 shares
CY2017Q1 ogen Proceeds From Payment Of Stock Subscription Receivable
ProceedsFromPaymentOfStockSubscriptionReceivable
30563
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In June of 2016, the Company sold its consumer probiotics business, as such the Company is no longer dependent on key suppliers to continue to operate the consumer probiotics business.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of March&#xA0;31, 2018, the uninsured portion of this balance was $4,507,863. As of December&#xA0;31, 2017, the uninsured portion of this balance was $5,916,143.</p> </div>
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1408280
CY2018Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
330
CY2018Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
268096
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7709
CY2018Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
58670
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
ORAGENICS INC
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001174940
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
795463
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2119397
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.42
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
293397
CY2018Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2119397
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-333317
CY2018Q1 us-gaap Interest Expense
InterestExpense
837
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3474
CY2018Q1 us-gaap Interest Paid
InterestPaid
4495
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Organization</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Oragenics, Inc. (formerly known as Oragen, Inc.) (the &#x201C;Company&#x201D; or &#x201C;we&#x201D;) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.</p> </div>
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-41630
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2121704
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1366650
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2119397
CY2018Q1 us-gaap Notes Assumed1
NotesAssumed1
28915
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2121704
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2307
CY2018Q1 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-41630
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1326241
CY2018Q1 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
118324
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
33330 shares
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
118324
CY2018Q1 dei Trading Symbol
TradingSymbol
OGEN
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4991475 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with US&#xA0;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, and income tax valuation allowance. Inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts were the principal areas of estimation that had been reflected in the financial statements related to discontinued operations.</p> </div>
CY2018Q1 ogen Class Of Warrant Exercised
ClassOfWarrantExercised
0 shares
CY2018Q1 ogen Par Value Of Common Stock Issued
ParValueOfCommonStockIssued
259

Files In Submission

Name View Source Status
0001193125-18-164075-index-headers.html Edgar Link pending
0001193125-18-164075-index.html Edgar Link pending
0001193125-18-164075.txt Edgar Link pending
0001193125-18-164075-xbrl.zip Edgar Link pending
d493615d10q.htm Edgar Link pending
d493615dex311.htm Edgar Link pending
d493615dex312.htm Edgar Link pending
d493615dex321.htm Edgar Link pending
d493615dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ogen-20180331.xml Edgar Link completed
ogen-20180331.xsd Edgar Link pending
ogen-20180331_cal.xml Edgar Link unprocessable
ogen-20180331_def.xml Edgar Link unprocessable
ogen-20180331_lab.xml Edgar Link unprocessable
ogen-20180331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending